JP2025508660A5 - - Google Patents
Info
- Publication number
- JP2025508660A5 JP2025508660A5 JP2024543311A JP2024543311A JP2025508660A5 JP 2025508660 A5 JP2025508660 A5 JP 2025508660A5 JP 2024543311 A JP2024543311 A JP 2024543311A JP 2024543311 A JP2024543311 A JP 2024543311A JP 2025508660 A5 JP2025508660 A5 JP 2025508660A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- administration
- amount
- therapeutically effective
- cyclodextrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263311536P | 2022-02-18 | 2022-02-18 | |
| US63/311,536 | 2022-02-18 | ||
| PCT/IB2023/051467 WO2023156970A1 (en) | 2022-02-18 | 2023-02-17 | Treatment of hypertriglyceridemia with 2-hydroxypropyl-beta-cyclodextrin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508660A JP2025508660A (ja) | 2025-04-10 |
| JP2025508660A5 true JP2025508660A5 (https=) | 2026-02-24 |
Family
ID=85476260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024543311A Pending JP2025508660A (ja) | 2022-02-18 | 2023-02-17 | ２－ヒドロキシプロピル－β－シクロデキストリンによる高トリグリセリド血症の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240398849A1 (https=) |
| EP (1) | EP4479064A1 (https=) |
| JP (1) | JP2025508660A (https=) |
| KR (1) | KR20240148426A (https=) |
| CN (1) | CN118715017A (https=) |
| AU (1) | AU2023222567A1 (https=) |
| CA (1) | CA3244447A1 (https=) |
| IL (1) | IL315046A (https=) |
| MX (1) | MX2024010110A (https=) |
| TW (1) | TW202342072A (https=) |
| WO (1) | WO2023156970A1 (https=) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003063824A2 (en) * | 2002-02-01 | 2003-08-07 | Shimoda Biotech (Pty) Ltd | Pharmaceutical composition |
| CN1745746A (zh) * | 2004-09-09 | 2006-03-15 | 天津药物研究院 | 冰片的羟丙基－β－环糊精包合物及其制剂和制备方法 |
| CN1961892A (zh) * | 2005-11-08 | 2007-05-16 | 天津药物研究院 | 降香羟丙基－β－环糊精包合物及其制剂和制备方法 |
| GB0710439D0 (en) * | 2007-05-31 | 2007-07-11 | Uni I Oslo | Oral dosage form |
| US8975241B2 (en) * | 2009-10-08 | 2015-03-10 | Song Ho Biomed Co., Ltd. | Composition for treating and preventing obesity including high water-soluble 2-hydroxypropyl-betacyclodextrin as effective component |
| FR3014694B1 (fr) * | 2013-12-13 | 2016-11-11 | Roquette Freres | Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl |
-
2023
- 2023-02-17 CN CN202380022294.5A patent/CN118715017A/zh active Pending
- 2023-02-17 CA CA3244447A patent/CA3244447A1/en active Pending
- 2023-02-17 AU AU2023222567A patent/AU2023222567A1/en active Pending
- 2023-02-17 WO PCT/IB2023/051467 patent/WO2023156970A1/en not_active Ceased
- 2023-02-17 MX MX2024010110A patent/MX2024010110A/es unknown
- 2023-02-17 EP EP23708901.6A patent/EP4479064A1/en active Pending
- 2023-02-17 KR KR1020247030936A patent/KR20240148426A/ko active Pending
- 2023-02-17 IL IL315046A patent/IL315046A/en unknown
- 2023-02-17 JP JP2024543311A patent/JP2025508660A/ja active Pending
- 2023-02-18 TW TW112105977A patent/TW202342072A/zh unknown
-
2024
- 2024-08-12 US US18/801,161 patent/US20240398849A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6795571B2 (ja) | グリブリドおよび他の薬剤の静脈内投与方法 | |
| CN104159598A (zh) | 治疗糖尿病的方法和组合物 | |
| JP6440843B2 (ja) | 脂肪代謝の調節に供する医薬品の製造のための第一鉄アミノ酸キレートを含む組成物の使用 | |
| JP2023501457A5 (https=) | ||
| CN114728012A (zh) | 用于治疗癫痫持续状态的加奈索酮 | |
| JP7639156B2 (ja) | チルゼパチド治療方法 | |
| ES2202449T3 (es) | Inhibidor de edema cerebral. | |
| US20190240243A1 (en) | Agent for treating retinopathy | |
| JP2025508660A5 (https=) | ||
| JP2023541170A5 (https=) | ||
| BRPI0721741A2 (pt) | mÉtodo de tratamento de diabetes | |
| WO2024042518A1 (en) | Glp-1 receptor antagonist and methods of use thereof | |
| US11903945B2 (en) | Methods of treating antipsychotic-induced weight gain with miricorilant | |
| WO2024078507A1 (zh) | 麦角甾醇在制备防治胃溃疡药物中的应用 | |
| US20120283332A1 (en) | Transdermal delivery of metformin | |
| JP2023543131A5 (https=) | ||
| CA3158745C (en) | Methods of treating antipsychotic-induced weight gain with miricorilant | |
| WO1999030698A1 (en) | A drug for treating diabetic nephrosis and delaying renal failure | |
| CN101485679A (zh) | 一种预防和治疗高血脂的药物 | |
| WO2026092666A1 (zh) | 一种化合物或其药学上可接受的盐在治疗糖代谢型疾病中的应用 | |
| TW202604485A (zh) | 患有肝損傷患者肝疾病之治療 | |
| Ishimura et al. | Importance of medication and drug management of the oral formulation of glucagon-like peptide-1 receptor agonist, semaglutide, after switching from the injectable formulation | |
| WO2026037397A1 (zh) | Glp-1类似物的医药用途 | |
| WO2025238200A1 (en) | Treatment of a liver disease in patients with hepatic impairment | |
| JP2023543132A5 (https=) |